Kura OncologyKURA
KURA
About: Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Employees: 192
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
7% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 57
3% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 36
1% less funds holding
Funds holding: 185 [Q4 2024] → 184 (-1) [Q1 2025]
7% less call options, than puts
Call options by funds: $596K | Put options by funds: $640K
1.68% less ownership
Funds ownership: 101.34% [Q4 2024] → 99.66% (-1.68%) [Q1 2025]
23% less capital invested
Capital invested by funds: $686M [Q4 2024] → $531M (-$155M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
73%
upside
Avg. target
$26
312%
upside
High target
$36
465%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Robert Driscoll | 465%upside $36 | Outperform Reiterated | 20 Jun 2025 |
JMP Securities Reni Benjamin | 340%upside $28 | Market Outperform Reiterated | 4 Jun 2025 |
Mizuho Mara Goldstein | 371%upside $30 | Outperform Maintained | 19 May 2025 |
Barclays Peter Lawson | 73%upside $11 | Overweight Maintained | 2 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on July 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 141,750 shares of common stock to eight (8) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
4 weeks ago
Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Kura Oncology is a Strong Buy due to ziftomenib's positive Phase 2 data in newly diagnosed AML mutant patients and upcoming FDA Priority Review for relapsed/refractory NPM1-m/KMT2A-r AML. The pipeline is expanding beyond monotherapy, with promising results in combination regimens for newly diagnosed AML patients. Strong financials, including $703M in cash and a supportive partnership with Kyowa Kirin, minimize dilution risk and support operations through commercialization for 1st-line setting.
Neutral
Zacks Investment Research
1 month ago
Is the Options Market Predicting a Spike in Kura Oncology Stock?
Investors need to pay close attention to KURA stock based on the movements in the options market lately.
Neutral
GlobeNewsWire
1 month ago
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML –
Positive
Zacks Investment Research
1 month ago
KURA Stock Rises More Than 15% This Past Week: Here's Why
Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Neutral
GlobeNewsWire
1 month ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 79,200 shares of common stock to five (5) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically meaningful QTc prolongation; 3% of patients discontinued due to treatment-related adverse events – – Potential first approval of a once-daily, oral menin inhibitor for treatment of adult patients with relapsed or refractory NPM1-mutated AML with Priority Review and a PDUFA target action date of November 30, 2025 – – Kura Oncology to host virtual investor event today at 7:30pm ET / 4:30pm PT – SAN DIEGO and TOKYO, June 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) announced the presentation of positive pivotal results from the KOMET-001 Phase 2 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML) in an oral session today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from May 30 - June 3, 2025.
Neutral
GlobeNewsWire
1 month ago
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – SAN DIEGO and TOKYO, June 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced the U.S. Food and Drug Administration (FDA) has accepted Kura's New Drug Application (NDA) seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation.
Neutral
GlobeNewsWire
2 months ago
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
– Results from KOMET-001 registration-directed trial of ziftomenib in R/R NPM1-m AML patients selected for oral presentation on Monday, June 2nd –
Neutral
GlobeNewsWire
2 months ago
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming investor conferences:
Charts implemented using Lightweight Charts™